PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 4, 2011Clinical Chemistry109 citationsOpen Access

Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture

View Full Paper
JMJanice MayneTDThilina DewpuraARAngela Raymond

Structured PICO

Does the PCSK9 Q152H variant reduce plasma PCSK9 and LDLC concentrations in humans and impair processing in cell culture?

P
Population
15 members of a white French-Canadian family, unrelated noncarriers (n=210), and cell culture models
I
Intervention
Presence of PCSK9 Q152H sequence variant
C
Comparator
Unrelated noncarriers (n=210) and wild-type PCSK9 (PCSK9-WT) in cell culture
O
Outcome
Plasma PCSK9 and LDLC concentrations, and in vitro processing/secretion of PCSK9surrogate

The novel PCSK9-Q152H variant significantly lowers plasma PCSK9 and LDL cholesterol levels through impaired autocatalytic processing and secretion.

Abstract

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) is a polymorphic gene whose protein product regulates plasma LDL cholesterol (LDLC) concentrations by shuttling liver LDL receptors (LDLRs) for degradation. PCSK9 variants that cause a gain or loss of PCSK9 function are associated with hyper- or hypocholesterolemia, which increases or reduces the risk of cardiovascular disease, respectively. We studied the clinical and molecular characteristics of a novel PCSK9 loss-of-function sequence variant in a white French-Canadian family. METHODS: In vivo plasma and ex vivo secreted PCSK9 concentrations were measured with a commercial ELISA. We sequenced the PCSK9 exons for 15 members of a family, the proband of which exhibited very low plasma PCSK9 and LDLC concentrations. We then conducted a structure/function analysis of the novel PCSK9 variant in cell culture to identify its phenotypic basis. RESULTS: We identified a PCSK9 sequence variant in the French-Canadian family that produced the PCSK9 Q152H substitution. Family members carrying this variant had mean decreases in circulating PCSK9 and LDLC concentrations of 79% and 48%, respectively, compared with unrelated noncarriers (n=210). In cell culture, the proPCSK9-Q152H variant did not undergo efficient autocatalytic cleavage and was not secreted. Cells transiently transfected with PCSK9-Q152H cDNA had LDLR concentrations that were significantly higher than those of cells overproducing wild-type PCSK9 (PCSK9-WT). Cotransfection of PCSK9-Q152H and PCSK9-WT cDNAs produced a 78% decrease in the secreted PCSK9-WT protein compared with control cells. CONCLUSIONS: Collectively, our results demonstrate that the PCSK9-Q152H variant markedly lowers plasma PCSK9 and LDLC concentrations in heterozygous carriers via decreased autocatalytic processing and secretion, and hence, inactivity on the LDLR.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mayne et al. (2011) studied this question.

synapsesocial.com/papers/6a1954efa0353395e9583158https://doi.org/10.1373/clinchem.2011.165191
Ask AI
Helpful
Bookmark
Share
View Full Paper